Opaleye Management Inc. 13D and 13G filings for Jounce Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-09 4:05 pm Sale |
2023-12-31 | 13G | Jounce Therapeutics, Inc. JNCE |
Opaleye Management Inc. | 0 0.000% |
-2,810,000 (Position Closed) |
Filing |
| 2023-04-12 4:15 pm Purchase |
2022-03-30 | 13G | Jounce Therapeutics, Inc. JNCE |
Opaleye Management Inc. | 2,810,000 5.390% |
2,810,000 (New Position) |
Filing |